Kathleen P. Bloch net worth and biography

Kathleen Bloch Biography and Net Worth

CFO of Cytosorbents

Ms. Bloch has more than 20 years of executive financial experience at both public and private companies. From 2008 to 2010, she served as the Chief Operating Officer of PC Group, Inc., where she was hired as CFO in 2007. Prior to this, Ms. Bloch managed the day-to-day operations for The Silverman Group, a real estate and investment company. For ten years prior she was employed by Silver Line Building Products Corporation, a leading privately-held manufacturer of vinyl windows. She served as CFO from 1999 until 2006 when the company was acquired by Andersen Corporation, a leading manufacturer of windows. She holds a Master of Business Administration degree and a Bachelor of Science Accounting degree from LaSalle University.

What is Kathleen P. Bloch's net worth?: The estimated net worth of Kathleen P. Bloch is at least $45,096.50 as of May 25th, 2023. Ms. Bloch owns 47,000 shares of Cytosorbents stock worth more than $45,097 as of November 14th. This net worth approximation does not reflect any other assets that Ms. Bloch may own. Additionally, Ms. Bloch receives a salary of $587,920.00 as CFO at Cytosorbents. Learn More about Kathleen P. Bloch's net worth.
How old is Kathleen P. Bloch?: Ms. Bloch is currently 69 years old. There are 4 older executives and no younger executives at Cytosorbents. The oldest executive at Cytosorbents is Dr. Robert H. Bartlett M.D., Co-Chairman of Cardiac Surgery Advisory Board & Consultant, who is 85 years old. Learn More on Kathleen P. Bloch's age.
What is Kathleen P. Bloch's salary?: As the CFO of Cytosorbents Co., Ms. Bloch earns $587,920.00 per year. The highest earning executive at Cytosorbents is Dr. Phillip P. Chan M.D., Ph.D., CEO & Director, who commands a salary of $651,780.00 per year. Learn More on Kathleen P. Bloch's salary.
How do I contact Kathleen P. Bloch?: The corporate mailing address for Ms. Bloch and other Cytosorbents executives is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. Cytosorbents can also be reached via phone at (732) 329-8885 and via email at [email protected]. Learn More on Kathleen P. Bloch's contact information.
Has Kathleen P. Bloch been buying or selling shares of Cytosorbents?: Kathleen P. Bloch has not been actively trading shares of Cytosorbents within the last three months. Most recently, on Thursday, May 25th, Kathleen P. Bloch bought 3,300 shares of Cytosorbents stock. The stock was acquired at an average cost of $2.85 per share, with a total value of $9,405.00. Following the completion of the transaction, the chief financial officer now directly owns 47,000 shares of the company's stock, valued at $133,950. Learn More on Kathleen P. Bloch's trading history.
Who are Cytosorbents' active insiders?: Cytosorbents' insider roster includes Kathleen Bloch (CFO), and Phillip Chan (CEO). Learn More on Cytosorbents' active insiders.
Are insiders buying or selling shares of Cytosorbents?: During the last twelve months, Cytosorbents insiders bought shares 1 times. They purchased a total of 22,557 shares worth more than $30,000.81. The most recent insider tranaction occured on December, 13th when Director Alan D Sobel bought 22,557 shares worth more than $30,000.81. Insiders at Cytosorbents own 6.6% of the company. Learn More about insider trades at Cytosorbents.
Information on this page was last updated on 12/13/2023.

Kathleen P. Bloch Insider Trading History at Cytosorbents

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/25/2023	Buy	3,300	$2.85	$9,405.00	47,000
5/10/2023	Buy	10,000	$3.11	$31,100.00	43,700
6/6/2022	Buy	8,700	$1.90	$16,530.00	33,700
11/23/2021	Buy	4,000	$4.98	$19,920.00
12/10/2019	Buy	3,000	$3.68	$11,040.00
11/26/2019	Buy	1,000	$4.27	$4,270.00
8/16/2019	Buy	6,500	$4.83	$31,395.00
8/9/2019	Buy	1,500	$5.52	$8,280.00
5/10/2019	Buy	3,000	$6.49	$19,470.00
8/28/2018	Sell	10,000	$13.50	$135,000.00	260,004
8/3/2018	Sell	10,000	$12.54	$125,400.00	260,004
5/16/2018	Sell	12,400	$9.00	$111,600.00	265,704
5/14/2018	Sell	10,000	$8.50	$85,000.00	263,304
4/17/2018	Sell	120	$8.25	$990.00	253,424
3/15/2018	Sell	11,176	$8.25	$92,202.00	261,246
3/13/2018	Sell	1,104	$8.25	$9,108.00	251,174
2/21/2018	Sell	10,000	$8.00	$80,000.00	268,870
1/12/2018	Sell	12,400	$7.75	$96,100.00	241,038
1/8/2018	Sell	32,400	$7.30	$236,520.00	248,638
5/15/2017	Buy	1,000	$4.34	$4,340.00
12/6/2016	Buy	1,000	$4.83	$4,830.00	122,325
9/2/2014	Buy	65,000	$0.23	$14,950.00
5/20/2014	Buy	110,000	$0.24	$26,400.00

Kathleen P. Bloch Buying and Selling Activity at Cytosorbents

Cytosorbents Company Overview

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $0.95

$0.92

$0.99

50 Day Range

MA: $1.13

$0.74

$1.55

2 Week Range

Now: $0.95

$0.70

$2.15

Volume

74,329 shs

Average Volume

125,158 shs

Market Capitalization

$51.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.

Kathleen Bloch Biography and Net Worth

What is Kathleen P. Bloch's net worth?

How old is Kathleen P. Bloch?

What is Kathleen P. Bloch's salary?

How do I contact Kathleen P. Bloch?

Has Kathleen P. Bloch been buying or selling shares of Cytosorbents?

Who are Cytosorbents' active insiders?

Are insiders buying or selling shares of Cytosorbents?